West Orange, NJ, United States of America

Harpreet Kaur Sandhu

This inventor holds 18 USPTO granted patents and 21 published patent applications, plus 2 CIPO patents and 8 EPO patents. Top assignees: Hoffmann-La Roche Inc., Kashiv Specialty Pharmaceuticals, LLC, Kashiv Biosciences, LLC. Active years: 2002-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Harpreet Kaur Sandhu. Retrieved from https://idiyas.com/inventor/harpreet-kaur-sandhu

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 18 (Patent Applications = 21)

% Patents Active = 94.4

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 11)

Average Co-Inventor Count = 5.8

ph-index = 4

Forward Citations = 143(Granted Patents)

Company Filing History:

11 out of 5,026

Hoffmann-La Roche Inc.

patents

3 out of 10

Kashiv Specialty Pharmaceuticals, LLC

patents

2 out of 23

Kashiv Biosciences, LLC

Amneal Complex Products Research LLC

patents

where one patent can have more than one assignee

Years Active: 2002-2024

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12042559 - Gastroretentive dosage forms for sustained drug delivery (2024-07-23),

2. 11318091 - Gastroretentive dosage forms for sustained drug delivery (2022-05-03),

3. 11007145 - Gastroretentive dosage forms for sustained drug delivery (2021-05-18),

4. 10960001 - Opioid agonist / antagonist combination dosage forms (2021-03-30),

5. 10918597 - Gastroretentive dosage forms for sustained drug delivery (2021-02-16),

6. 10857098 - Gastroretentive dosage forms for sustained drug delivery (2020-12-08),

7. 10744131 - Abuse-resistant drug formulations (2020-08-18),

8. 10034854 - Pharmaceutical composition with improved bioavailability (2018-07-31),

9. 9663517 - Compositions and uses thereof (2017-05-30),

10. 9447089 - Compositions and uses thereof (2016-09-20),

11. 9427427 - Pharmaceutical composition with improved bioavailability (2016-08-30),

12. 8222230 - Pharmaceutical compositions with superior product performance and patient compliance (2012-07-17),

13. 6492530 - Amorphous form of cell cycle inhibitor having improved solubility and bioavailability (2002-12-10),

14. 6486329 - Amorphous form of cell cycle inhibitor having improved solubility and bioavailability (2002-11-26),

15. 6482847 - Amorphous form of cell cycle inhibitor having improved solubility and bioavailability (2002-11-19),

Title: Harpreet Kaur Sandhu: Innovator in Gastroretentive Drug Delivery

Introduction

Harpreet Kaur Sandhu, based in West Orange, NJ, is an accomplished inventor with a remarkable portfolio of 18 patents. His contributions primarily focus on advancements in drug delivery systems that enhance therapeutic efficacy through innovative formulations.

Latest Patents

Among his notable inventions, Sandhu's latest patents include the development of gastroretentive dosage forms for sustained drug delivery. This innovative approach involves floating gastroretentive systems designed to prolong gastric residence time, facilitating targeted drug release in the proximal gastrointestinal tract. The formulations encompass rapidly expanding sustained release and combined immediate release systems, optimized for maximum therapeutic benefit. The core of this technology lies in a permeable elastic membrane that provides the required characteristics for effective drug release while maintaining the mechanical integrity of the tablet.

Career Highlights

Throughout his career, Harpreet Kaur Sandhu has made significant contributions to the pharmaceutical industry. He has lent his expertise to notable companies including Hoffmann-La Roche Inc. and Kashiv Specialty Pharmaceuticals, LLC. His work in these organizations has had a lasting impact on drug formulation strategies aimed at improving patient outcomes.

Collaborations

Sandhu has also collaborated with distinguished professionals in the field, including Navnit Hargovindas Shah and Wantanee Phuapradit. These partnerships underscore his commitment to advancing research and innovation in drug delivery technologies.

Conclusion

Harpreet Kaur Sandhu's expertise and dedication to innovation in gastroretentive dosage forms exemplify the transformative power of technology in medicine. With a solid foundation of patents and a commitment to collaboration, he continues to push the boundaries of what is possible in drug delivery, ultimately enhancing therapeutic effectiveness for patients.

Profile summary based on public USPTO records.